

Antiphospholipid Syndromeâ€™“Not a Noninflammatory

Seminars in Thrombosis and Hemostasis

41, 607-614

DOI: 10.1055/s-0035-1556725

Citation Report

#	ARTICLE	IF	CITATIONS
1	Inflammation, Endothelial Dysfunction, and Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 547-548.	2.7	11
2	Effects of Disease Activity and Inflammatory Response on Hypercoagulability in Patients with Systemic Lupus Erythematosus. <i>Archives of Medical Research</i> , 2016, 47, 573-579.	3.3	8
3	Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2016, 75, 30-38.	6.5	88
4	Endothelin 1, ADMA and SDMA in pregnancies with obstetric and thrombotic antiphospholipid syndrome. <i>Journal of Reproductive Immunology</i> , 2016, 116, 86-92.	1.9	2
5	Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome—A Retrospective Analysis and a Review of Additional Treatment in Pregnancy. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 54-67.	6.5	14
6	Antiphospholipid syndrome: an update for clinicians and scientists. <i>Current Opinion in Rheumatology</i> , 2017, 29, 458-466.	4.3	18
7	Altered Î²2â€GlycoproteinÎ expression on microparticles in the presence of antiphospholipid antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1799-1806.	3.8	17
8	Major Histocompatibility Complex Class II Alleles Influence Induction of Pathogenic Antiphospholipid Antibodies in a Mouse Model of Thrombosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2052-2061.	5.6	9
9	Thrombin activatable fibrinolysis inhibitor (TAFI) â€” A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). <i>Thrombosis Research</i> , 2017, 158, 168-173.	1.7	14
10	Resolution of diffuse alveolar haemorrhage after rituximab therapy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 409-410.	0.5	0
11	The Lupus Anticoagulant Paradox. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 445-452.	2.7	33
12	The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome. <i>Frontiers in Pediatrics</i> , 2018, 6, 362.	1.9	23
13	The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 2181-2189.	1.6	19
14	Peripheral B-Cell Subset Distribution in Primary Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2018, 19, 589.	4.1	15
15	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 433-440.	8.0	95
16	Antiphospholipid antibodies in adult IgA vasculitis: observational study. <i>Clinical Rheumatology</i> , 2019, 38, 347-351.	2.2	4
17	The Solitary Blue Toe: A Unique Presentation of Antiphospholipid Syndrome. <i>Journal of the American Podiatric Medical Association</i> , 2019, 109, 235-240.	0.3	3
19	Welcome to <i>Seminars in Thrombosis and Hemostasis 2019</i> —New (2017) Impact Factor and Most Highly Cited Papers. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 001-004.	2.7	3

#	ARTICLE	IF	CITATIONS
20	Obstetric outcomes in patients with primary thrombotic and obstetric antiphospholipid syndrome and its relation to the antiphospholipid antibody profile. <i>Lupus</i> , 2019, 28, 868-877.	1.6	14
21	Altered Th17/Treg Ratio in Peripheral Blood of Systemic Lupus Erythematosus but Not Primary Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 391.	4.8	43
22	Antiphospholipid syndrome: Diagnosis and management in the obstetric patient. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 64, 31-40.	2.8	18
23	Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: A systematic review and network meta-analysis. <i>American Journal of Reproductive Immunology</i> , 2020, 83, e13219.	1.2	19
24	NETs in APS: Current Knowledge and Future Perspectives. <i>Current Rheumatology Reports</i> , 2020, 22, 67.	4.7	31
25	Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 772-781.	2.1	9
26	Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412092212.	2.0	1
27	Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation. <i>Thrombosis Research</i> , 2021, 198, 55-61.	1.7	7
28	Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 607-616.	3.8	45
29	Tissue injury—the biology. , 2021, , 271-285.		0
30	Systemic lupus erythematosus: still a problem for doctors. <i>Russian Journal of Human Reproduction</i> , 2021, 27, 102.	0.3	0
31	Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 395-406.	3.0	6
32	Microparticles: An Alternative Explanation to the Behavior of Vascular Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 787-799.	2.7	2
33	Thrombosis: Grand Challenges Ahead!. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 637005.	2.4	1
34	The Predictive Value of the aCL and Anti-Î²2GPI at the Time of Acute Deep Vein Thrombosis—A Two-Year Prospective Study. <i>Biomedicines</i> , 2021, 9, 901.	3.2	2
35	Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1357-1367.	2.0	7
36	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3
37	Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. <i>JCI Insight</i> , 2017, 2, .	5.0	75

#	ARTICLE	IF	CITATIONS
38	Thrombophilie, thromboembolische Erkrankungen und antithrombotische Therapie. , 2015, , 1047-1068.		0
39	Thrombophilie, thromboembolische Erkrankungen und antithrombotische Therapie. , 2017, , 1073-1096.		0
40	Thrombophilie, thromboembolische Erkrankungen und antithrombotische Therapie. , 2020, , 1121-1145.		0
41	Impact of Nitric Oxide Synthesis Modulators on the Mechanisms of Apoptosis Development and Production of Reactive Oxygen Species in the Blood Leukocytes in Experimental Antiphospholipid Syndrome. Experimental and Clinical Physiology and Biochemistry, 2020, 2019, .	0.0	0
42	Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries. Journal of Internal Medicine, 2022, 291, 327-337.	6.0	3
43	Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Seminars in Immunopathology, 2022, 44, 347-362.	6.1	67
44	Obstetric Antiphospholipid Syndrome. , 0, , .		0
45	Antiphospholipid Syndrome in a Patient With Autosomal Dominant Polycystic Kidney Disease: The Surface of the Moon. Cureus, 2022, 14, e24014.	0.5	0
47	Combined Oral Contraceptive-Associated Venous Thromboembolism Revealing an Antiphospholipid Syndrome: International Retrospective Study of Outcomes. SSRN Electronic Journal, 0, , .	0.4	0
48	Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome. Journal of Cellular and Molecular Medicine, 2022, 26, 4357-4370.	3.6	10
49	Combined oral contraceptive-associated venous thromboembolism revealing an antiphospholipid syndrome: International retrospective study of outcomes.. Thrombosis Research, 2022, 219, 102-108.	1.7	3
50	Clinical analysis of relationship between clot formation in COVID-19 patients and presence of antiphospholipid. International Journal of Health Sciences, 0, , 11133-11140.	0.1	0
51	Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum. Obstetrics and Gynecology, 2023, 141, 85-108.	2.4	4
52	Interaction between endothelial cell-derived extracellular vesicles and monocytes: A potential link between vascular thrombosis and pregnancy-related morbidity in antiphospholipid syndrome. Autoimmunity Reviews, 2023, 22, 103274.	5.8	1
53	Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome. Frontiers in Immunology, 0, 13, .	4.8	6
54	Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ, The, 0, , e069717.	6.0	33
55	Thrombophilie, thromboembolische Erkrankungen und antithrombotische Therapie. , 2024, , 1177-1202.		0